Crossing Over to Large Molecules
Improvements in genetic engineering techniques have fueled the growth of well-characterized large molecules since the 1980s. Today, revenues from the sale of biopharmaceuticals in the United States exceed $100 billion annually. 1Global sales are growing at a rate of more than 8%, double the rate of traditional pharmaceuticals. 2 To reduce business risk, big pharmaceutical companies have added biopharmaceuticals and vaccines—the so-called natural biological products—to their portfolios.
- 1. Ernst & Young Global Limited (EY). "Key Dealmaking Insights," in Biotechnology Report 2016: Beyond Borders. http://www.ey.com/Publication/vwLUAssets/EY-beyond-borders- 2016/$FILE/EY-beyond-borders-2016.pdf
- 2. Otto, Ralf, Alberto Santagostino, , and Ulf Schrader. "Rapid Growth in Biopharma: Challenges and Opportunities." Our Insights. December 2014. McKinsey & Company. http://www. mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/rapidgrowth- in-biopharma